eLife22h
Synthetic gene circuits that selectively target RAS-driven cancers
This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...
Cure Today1d
Explaining KRAS Mutations For Patients With Colorectal Cancer
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
eLife5d
Intrinsic bioenergetic adaptations compensate for reduced mitochondrial content in HER2-driven mammary tumors
However, mechanistic studies to support the conclusion that mitochondrial function is increased in the tumours remain incomplete and would benefit from experiments that would directly interrogate ...
Armed robbery in Revesby8d
Pfizer's BRAFTOVI Regimen Boosts Survival in Phase 3 Trial
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
Pfizer: BRAFTOVI Combination Regimen Shows Significant Improvement In PFS In Phase 3 Trial In MCRC
Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...
Le Lézard9d
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...
C&EN15d
Blocking the p38 MAPK Signaling Pathway in the Rat Hippocampus Alleviates the Depressive-like Behavior Induced by Spinal Cord Injury
Department of Neurosurgery, Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College, No. 152 Aiguo Road, Nanchang, Jiangxi 330006, China Department of ...
The Bakersfield Californian20d
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and ...
The Daily News20d
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...
Business Standard20d
Canada PR: 4 new permanent residency pathways to be introduced in 2025
Want to apply for Canada PR? The country is set to introduce four new permanent residency (PR) pathways in 2025, even as the government plans to reduce its PR targets from 485,000 to 465,000, ...
Cancer Research21d
Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis
1Department of Oncology, University of Oxford, Oxford, United Kingdom. *Corresponding Author: Connor E. Woolley, Department of Oncology, University of Oxford, Old Road Campus Research Building, ...